drugset / Trial / NCT07006727
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.
Timeline
- Start
- 2025-10-16
- Primary completion
- 2031-08-29
- Completion
- 2031-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 111In-ETN029 | Diagnostic / imaging agent | — | — |
| Subject | 225Ac-ETN029 | Other / unclassified | — | — |